Last reviewed · How we verify
Ketorolac postoperative
Ketorolac postoperative is a Small molecule drug developed by Fondazione IRCCS Policlinico San Matteo di Pavia. It is currently FDA-approved. Also known as: Toradol.
Ketorolac postoperative, marketed by Fondazione IRCCS Policlinico San Matteo di Pavia, is a non-steroidal anti-inflammatory drug (NSAID) used for pain management after surgery. The key composition patent for Ketorolac postoperative is set to expire in 2028, providing a clear period of exclusivity and potential revenue protection. The primary risk is the entry of generic competitors upon patent expiry, which could significantly erode market share and revenue.
At a glance
| Generic name | Ketorolac postoperative |
|---|---|
| Also known as | Toradol |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
- Postoperative Pain Will be Compared in Cholecystectomy Patients: Half Receiving TAP Block and Half Without it. (NA)
- Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy (PHASE2, PHASE3)
- Phase 2 Herniorrhaphy Study for Opioid Elimination (PHASE2)
- Post-Operative Pain Relief: Zynrelef or Periarticular Injections in RATKA (PHASE4)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac postoperative CI brief — competitive landscape report
- Ketorolac postoperative updates RSS · CI watch RSS
- Fondazione IRCCS Policlinico San Matteo di Pavia portfolio CI
Frequently asked questions about Ketorolac postoperative
What is Ketorolac postoperative?
Who makes Ketorolac postoperative?
Is Ketorolac postoperative also known as anything else?
What development phase is Ketorolac postoperative in?
Related
- Manufacturer: Fondazione IRCCS Policlinico San Matteo di Pavia — full pipeline
- Also known as: Toradol
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing